Moderna and CytomX partner for mRNA-based conditnionally activated therapeutics

Collaboration to generate and develop therapeutics for oncology and non-oncology conditions

KIMS invests further in Sarvejana Healthcare

The company now holds 56.61% of the total paid-up equity share capital of Sarvejana Healthcare

Chindex Medical acquires 10 ViewRay MRIdian Systems for advanced cancer treatment

Purchase agreement with ViewRay will make state-of-the art precision radiation therapy available in China

PharmaEssentia sets up a new R&D facility in the Boston Area

The PharmaEssentia Innovation Research Center (PIRC) will advance the company’s diverse pipeline and research footprint in the U.S., driving job creation

Sakar Healthcare starting Liquid & Lyophilised Injection unit

The unit will have installed manufacturing capacity of over 15 million vials annually that includes lyophilized vials, all in the anti-cancer segment

Blacksmith announces merger with Forge Therapeutics

To create leading company developing medicines targeting metalloenzymes

Pfizer announces positive topline results from Phase 3 study of Hemophilia B gene therapy candidate

Lynparza in combination with Abiraterone and Prednisone approved in the EU as treatment for metastatic castration-resistant prostate cancer

First PARP inhibitor and new hormonal agent combination approved for these patients in Europe

Ezharima launched in Japan as first dual EZH1 and EZH2 inhibitor therapy for leukemiaLymphoma

EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years

Enhertu to demonstrate a significant survival benefit vs. chemotherapy